

Enriqueta Felip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041998/publications.pdf>

Version: 2024-02-01

260
papers

67,869
citations

4388

86
h-index

736

251
g-index

265
all docs

265
docs citations

265
times ranked

38705
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	27.0	7,973
2	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	13.7	5,456
3	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	27.0	5,183
4	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	10.7	4,943
5	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
6	First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	27.0	2,808
7	First-Line Nivolumab in Stage IV or Recurrent Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
8	AZD9291 in EGFR Inhibitorâ€“Resistant Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1689-1699.	27.0	1,802
9	Ceritinib in <i>ALK</i>-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197.	27.0	1,367
10	Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonâ€“small cell lung cancer harboring EGFR T790M. Nature Medicine, 2015, 21, 560-562.	30.7	1,280
11	Atezolizumab for First-Line Treatment of PD-L1â€“Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339.	27.0	959
12	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	27.0	871
13	Five-Year Overall Survival for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 2019, 37, 2518-2527.	1.6	811
14	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	10.7	773
15	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0.784314 ngBT /Over	27.0	743
16	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 1505-1517.	1.6	710
17	Brigatinib versus Crizotinib in <i>ALK</i>-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	27.0	691
18	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€“IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet, The, 2021, 398, 1344-1357.	13.7	689

#	ARTICLE	IF	CITATIONS
19	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii56-vii64.	1.2	647
20	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	7.1	599
21	First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	27.0	592
22	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1654-1667.	10.7	587
23	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	1.6	572
24	Capmatinib in<i>MET</i>Exon 14â€“Mutated or<i>MET</i>-Amplified Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
25	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	10.7	535
26	Tepotinib in Nonâ€“Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	27.0	500
27	Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi99-vi105.	1.2	490
28	Osimertinib in Pretreated T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	1.6	470
29	Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v103-v115.	1.2	456
30	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 874-886.	10.7	453
31	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	1.6	445
32	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi89-vi98.	1.2	440
33	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
34	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 452-463.	10.7	418
35	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	10.7	418
36	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	1.2	410

#	ARTICLE	IF	CITATIONS
37	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 241-251.	27.0	393
38	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 897-907.	10.7	389
39	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate) Tj ETQq1 1 0.784314 rgBT /Overl Oncology, 2018, 29, 959-965.	1.2	388
40	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3138-3145.	1.6	351
41	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	1.6	348
42	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 723-733.	1.6	329
43	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.9	327
44	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of Clinical Oncology, 2016, 34, 2866-2873.	1.6	316
45	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	1.2	308
46	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in <i>ALK</i> -Mutation-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258.	1.6	308
47	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics, 2004, 13, 2443-2449.	2.9	291
48	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	1.6	282
49	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v116-v119.	1.2	273
50	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i> -Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3101-3109.	1.6	252
51	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	1.2	246
52	Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 2015, 1, 149.	7.1	224
53	Brigatinib Versus Crizotinib in Advanced <i>ALK</i> Inhibitor-Naive <i>ALK</i> -Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 2020, 38, 3592-3603.	1.6	224
54	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i> -Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology, 2016, 34, 2858-2865.	1.6	216

#	ARTICLE	IF	CITATIONS
55	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. <i>Clinical Cancer Research</i> , 2014, 20, 2001-2010.	7.0	215
56	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021, 32, 881-895.	1.2	213
57	Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	210
58	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	1.2	210
59	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017, 28, 874-881.	1.2	197
60	CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. <i>Annals of Oncology</i> , 2018, 29, 687-693.	1.2	193
61	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	2.0	189
62	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
63	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2015, 10, e0121071.	2.5	185
64	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating <i>EGFR</i> mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	10.7	172
65	Tepotinib plus gefitinib in patients with <i>EGFR</i> -mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous <i>EGFR</i> inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlock	10.7	169
66	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	7.1	160
67	Osimertinib and other third-generation <i>EGFR</i> TKI in <i>EGFR</i> -mutant NSCLC patients. <i>Annals of Oncology</i> , 2018, 29, i20-i27.	1.2	159
68	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , 2016, 17, 212-223.	10.7	158
69	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	1.1	156
70	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	10.7	137
71	Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv68-iv70.	1.2	136
72	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3131-3137.	1.6	136

#	ARTICLE	IF	CITATIONS
73	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
74	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	1.2	129
75	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
76	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	1.1	119
77	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 387-397.	10.7	119
78	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 767-776.	2.3	118
79	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. <i>Annals of Oncology</i> , 2011, 22, 1507-1519.	1.2	117
80	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017, 8, 410.	12.8	117
81	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer – The ETOP NICOLAS trial. <i>Lung Cancer</i> , 2019, 133, 83-87.	2.0	113
82	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
83	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1434-1448.	1.1	107
84	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	3.7	101
85	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	1.1	99
86	Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 7503-7503.	1.6	97
87	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	4.5	91
88	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019, 30, 281-289.	1.2	88
89	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). <i>Annals of Oncology</i> , 2015, 26, 1741-1748.	1.2	87
90	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 55-65.	3.6	86

#	ARTICLE	IF	CITATIONS
91	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1–Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	1.1	85
92	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 341-352.	4.2	82
93	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
94	Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v120-v125.	1.2	81
95	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	1.1	78
96	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	1.6	74
97	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 3867-3874.	7.0	73
98	Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390). <i>Journal of Thoracic Oncology</i> , 2012, 7, 203-211.	1.1	70
99	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	7.0	70
100	Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e52261.	2.5	68
101	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.	1.2	67
102	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , 2012, 6, 15-26.	4.6	66
103	NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)–positive NSCLC. <i>Annals of Oncology</i> , 2016, 27, vi577.	1.2	66
104	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
105	Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333.	2.6	65
106	Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2012, 77, 192-198.	2.0	64
107	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	1.1	62
108	Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii39-ii40.	1.2	61

#	ARTICLE	IF	CITATIONS
109	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	1.2	60
110	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. <i>Annals of Oncology</i> , 2021, 32, 620-630.	1.2	60
111	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	2.4	59
112	Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. <i>Nature Communications</i> , 2020, 11, 3157.	12.8	59
113	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017, 28, 2451-2457.	1.2	58
114	1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 1973-1980.	1.2	56
115	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	3.3	55
116	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	7.3	54
117	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	7.1	53
118	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 392-403.	1.1	51
119	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALK-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8060-8060.	1.6	51
120	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	1.1	50
121	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128.	2.8	50
122	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
123	Safety and efficacy of naxitamab (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	10.7	47
124	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 1597-1607.	1.2	47
125	OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. <i>Journal of Thoracic Oncology</i> , 2017, 12, S253.	1.1	46
126	First-line crizotinib versus pemetrexed+cisplatin or pemetrexed+carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014, 32, 8002-8002.	1.6	44

#	ARTICLE	IF	CITATIONS
127	MARIPOSA: phase 3 study of first-line amivantamab+âazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	2.4	44
128	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i>V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	9.4	43
129	ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8059-8059.	1.6	43
130	HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. <i>Translational Lung Cancer Research</i> , 2013, 2, 122-7.	2.8	43
131	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9013-9013.	1.6	42
132	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. <i>Lung Cancer</i> , 2010, 70, 180-187.	2.0	41
133	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	2.8	41
134	A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2010, 21, 217-222.	1.2	40
135	Tissue sampling in lung cancer: A review in light of the MERIT experience. <i>Lung Cancer</i> , 2011, 74, 1-6.	2.0	40
136	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	2.0	40
137	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	2.8	39
138	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	3.7	37
139	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. <i>Annals of Oncology</i> , 2022, 33, 511-521.	1.2	36
140	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012, 14, 338-349.	2.4	35
141	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage NonâSmall-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	1.1	33
142	Adjuvant Therapy in NonâSmall Cell Lung Cancer: Future Treatment Prospects and Paradigms. <i>Clinical Lung Cancer</i> , 2011, 12, 261-271.	2.6	32
143	Lungscape: Resected NonâSmall-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
144	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2016, 96, 1-6.	2.0	31

#	ARTICLE	IF	CITATIONS
145	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 93-102.	3.0	31
146	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. Journal of Clinical Oncology, 2016, 34, 9026-9026.	1.6	31
147	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. Lung Cancer, 2017, 106, 70-75.	2.0	30
148	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	2.0	29
149	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 2017, 23, 5406-5415.	7.0	29
150	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer, 2018, 19, 74-83.e11.	2.6	28
151	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2016, 34, 9044-9044.	1.6	28
152	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALK-Naïve Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 609-617.	1.1	27
153	Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 2502-2502.	1.6	27
154	A consensus statement on the gender perspective in lung cancer. Clinical and Translational Oncology, 2017, 19, 527-535.	2.4	26
155	Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.. Journal of Clinical Oncology, 2016, 34, 9025-9025.	1.6	26
156	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer, 2017, 109, 101-108.	2.0	25
157	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology, 2018, 29, 200-208.	1.2	25
158	Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Annals of Oncology, 2014, 25, iv456.	1.2	24
159	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.6	24
160	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer, 2019, 134, 72-78.	2.0	24
161	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Molecular Oncology, 2021, 15, 887-900.	4.6	24
162	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	1.6	24

#	ARTICLE	IF	CITATIONS
163	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8003-8003.	1.6	24
164	Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1â€“. European Respiratory Journal, 2013, 42, 568-571.	6.7	23
165	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2015, 17, 103-112.	2.4	23
166	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, , .	0.7	23
167	Lung cancer in women: an overview with special focus on Spanish women. Clinical and Translational Oncology, 2014, 16, 517-528.	2.4	22
168	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	1.6	22
169	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology, 2016, 11, 801-807.	1.1	21
170	A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2010, 28, 3015-3015.	1.6	21
171	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. Journal of Clinical Oncology, 2017, 35, 9006-9006.	1.6	20
172	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	2.0	19
173	Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open, 2021, 6, 100131.	4.5	19
174	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clinical and Translational Oncology, 2013, 15, 977-984.	2.4	18
175	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. Breathe, 2016, 12, 249-255.	1.3	18
176	P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. Journal of Thoracic Oncology, 2016, 11, S241-S242.	1.1	18
177	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. Journal of Clinical Oncology, 2017, 35, 9011-9011.	1.6	18
178	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
179	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. Journal of Thoracic Oncology, 2020, 15, 416-425.	1.1	17
180	Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nslc) and Brain Metastases in the Ascend-1 Study. Annals of Oncology, 2014, 25, iv455.	1.2	17

#	ARTICLE	IF	CITATIONS
181	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with secondâ€“third line erlotinib. Lung Cancer, 2009, 66, 257-261.	2.0	16
182	Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. Journal of Infection, 2014, 69, 387-395.	3.3	16
183	Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Journal of Clinical Oncology, 2009, 27, 8098-8098.	1.6	16
184	A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physicianâ€™s choice in patients with advanced non-small cell lung cancer. Annals of Oncology, 2017, 28, 2241-2247.	1.2	15
185	OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations. Journal of Thoracic Oncology, 2018, 13, S347.	1.1	15
186	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.. Journal of Clinical Oncology, 2018, 36, 9021-9021.	1.6	15
187	Orbital Metastases from Transitional-Cell Cancer of the Urinary Bladder. Urologia Internationalis, 1991, 46, 82-84.	1.3	14
188	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2009, 11, 284-289.	2.4	14
189	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer, 2019, 136, 74-79.	2.0	14
190	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.6	14
191	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer, 2020, 144, 10-19.	2.0	14
192	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1â€™-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. Journal of Clinical Oncology, 2017, 35, 9090-9090.	1.6	14
193	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical and Translational Oncology, 2010, 12, 735-741.	2.4	13
194	The Evolving Role of Nivolumab in Nonâ€™Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2016, 17, 161-168.	2.6	13
195	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1â€™Selected Patients: Updated ORR, PFS and OS Dataâ€“from the BIRCH Study. Journal of Thoracic Oncology, 2017, 12, S251-S252.	1.1	13
196	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. Clinical and Translational Oncology, 2017, 19, 508-518.	2.4	13
197	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	4.5	13
198	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiotherapy and Oncology, 2020, 149, 84-88.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. <i>Clinical Lung Cancer</i> , 2000, 1, 287-293.	2.6	12
200	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , 2017, 55, 181-189.	7.7	12
201	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.	2.6	12
202	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 1390-1398.	2.4	12
203	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , 2003, 14, 1549-1554.	1.2	11
204	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). <i>Lung Cancer</i> , 2016, 99, 94-101.	2.0	11
205	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	2.4	11
206	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	2.8	11
207	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	7.1	11
208	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1479-1489.	3.1	10
209	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 398-402.	2.8	10
210	Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Española De Patología</i> , 2012, 45, 14-28.	0.2	9
211	Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1st-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (NscLc). <i>Annals of Oncology</i> , 2014, 25, iv427.	1.2	9
212	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.	1.3	9
213	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	2.8	9
214	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. <i>Thorax</i> , 2019, 74, 371-379.	5.6	9
215	Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. <i>Cancers</i> , 2021, 13, 3249.	3.7	9
216	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016, 36, 6647-6654.	1.1	9

#	ARTICLE	IF	CITATIONS
217	Female leadership in oncology“has progress stalled? Data from the ESMO W4O authorship and monitoring studies. ESMO Open, 2021, 6, 100281.	4.5	9
218	Encorafenib plus binimetinib in patients with<i>BRAF</i>^{V600}-mutant non-smallÂcell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9
219	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	2.8	8
220	Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) â€“ A decision-making analysis amongst European lung cancer experts. Lung Cancer, 2020, 146, 6-11.	2.0	8
221	Second-Line Treatment Options in Nonâ€“Small-CellÂLung Cancer: Report From anÂInternational Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	2.6	7
222	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open, 2021, 6, 100048.	4.5	7
223	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer, 2021, 157, 9-16.	2.0	7
224	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.. Journal of Clinical Oncology, 2016, 34, 9024-9024.	1.6	7
225	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	2.3	7
226	Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals of Oncology, 2016, 27, vi422.	1.2	6
227	Lung cancer in Spanish women: The WORLD07 project. European Journal of Cancer Care, 2019, 28, e12941.	1.5	6
228	Genetic landscape of patients with ALK-rearranged nonâ€“small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung Cancer, 2022, 163, 7-13.	2.0	6
229	SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical and Translational Oncology, 2022, 24, 635-645.	2.4	6
230	How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology, 2010, 21, vii230-vii233.	1.2	5
231	Thoracic Oncology HERMES: a European syllabus towards a harmonised education and training of Thoracic Oncology specialists. Breathe, 2013, 9, 381-392.	1.3	5
232	HIV-Positive Patients with Lung Cancer: IsÂImmunotherapy a Safe and Active OptionÂforÂThem?. Journal of Thoracic Oncology, 2018, 13, 874-876.	1.1	5
233	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5
234	DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?. Annals of Oncology, 2012, 23, 2211-2214.	1.2	4

#	ARTICLE	IF	CITATIONS
235	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017, 19, 1537-1542.	2.4	4
236	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 170-177.	2.0	4
237	Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2007, 18, ix143-ix146.	1.2	3
238	A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS). <i>Journal of Clinical Oncology</i> , 2008, 26, 8111-8111.	1.6	3
239	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12012-e12012.	1.6	3
240	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). <i>Lung Cancer</i> , 2022, 166, 107-113.	2.0	3
241	The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. <i>Annals of Oncology</i> , 2006, 17, x108-x112.	1.2	2
242	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016, 27, vi452.	1.2	2
243	Future care for long-term cancer survivors: towards a new model. <i>Clinical and Translational Oncology</i> , 2022, 24, 350-362.	2.4	2
244	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	2.8	1
245	Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 7679-7679.	1.6	1
246	Lung cancer in women: The Spanish female-specific database WORLD 07. <i>Journal of Clinical Oncology</i> , 2009, 27, 8084-8084.	1.6	1
247	Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7037-7037.	1.6	1
248	Never-smoking women with lung cancer from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1531-1531.	1.6	1
249	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12000-e12000.	1.6	1
250	El cáncer de pulmón en mujeres. <i>Arbor</i> , 2015, 191, a235.	0.3	0
251	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. <i>BMC Psychology</i> , 2020, 8, 123.	2.1	0
252	A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7248-7248.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Adjuvant and neoadjuvant therapy of non-small cell lung cancer. , 2012, , 93-103.		0
254	Adjuvant Chemotherapy: Feasibility in the Elderly and Patient Selection. , 2013, , 165-172.		0
255	Is There a Role for Neoadjuvant Chemotherapy in Older Patients?. , 2013, , 141-150.		0
256	Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2022, 12, 837630.	2.8	0
257	SEOM clinical guidelines (2021). Clinical and Translational Oncology, 2022, 24, 611-612.	2.4	0
258	ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery. Journal of Clinical Oncology, 2004, 22, 7142-7142.	1.6	0
259	BRCA1 and HIF-1 α mRNA expression and chemoresistance in non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology, 2004, 22, 7148-7148.	1.6	0
260	A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2004, 22, 7248-7248.	1.6	0